March 26, 2019 09:19 AM EDT
R&D

Is­raeli biotech flunks PhII liv­er can­cer study, but it in­sists drug Can-Fite dis­ease in sub­set of pa­tients

Natalie Grover

Reporter

Is­raeli biotech Can-Fite Bio­Phar­ma is hop­ing to trudge ahead with a late-stage study of its ex­per­i­men­tal can­cer drug, de­spite it fail­ing a mid-stage study in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times